A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission

A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission

Only modest advances in AML therapy have occurred in the past decade and relapse due to residual disease remains the major challenge. The potential of the immune system to address this is evident in the success of allogeneic transplantation, however this leads to considerable morbidity. Dendritic ce...

Full description

Bibliographic Details
Main Authors: Jennifer L. Hsu, Christian E. Bryant, Michael S. Papadimitrious, Benjamin Kong, Robin E. Gasiorowski, Daniel Orellana, Helen M. McGuire, Barbara Fazekas de St Groth, Douglas E. Joshua, P. Joy Ho, Stephen Larsen, Harry J. Iland, John Gibson, Georgina J. Clark, Phillip D. Fromm, Derek NJ Hart
Format: Article
Language:English
Published: Taylor & Francis Group 2018-04-01
Series:OncoImmunology
Subjects:
acute myeloid leukemia
blood dendritic cell
immunotherapy
allogeneic haematopoietic stem cell transplantation
chemotherapy
t cell landscape
checkpoint inhibitor
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1419114

Internet

http://dx.doi.org/10.1080/2162402X.2017.1419114

Similar Items